C
Cherie Paquette
Researcher at Brown University
Publications - 33
Citations - 710
Cherie Paquette is an academic researcher from Brown University. The author has contributed to research in topics: Population & Formulary. The author has an hindex of 11, co-authored 32 publications receiving 627 citations. Previous affiliations of Cherie Paquette include University of Arkansas for Medical Sciences & Tufts Center for the Study of Drug Development.
Papers
More filters
Journal ArticleDOI
The economics of follow-on drug research and development
Joseph A. DiMasi,Cherie Paquette +1 more
TL;DR: The data suggest that entry barriers have fallen over time for new drug introductions and the development histories of entrants to new drug classes suggest that development races better characterise new drug development than does a model of post hoc imitation.
Journal ArticleDOI
The economics of follow-on drug research and development: trends in entry rates and the timing of development.
Joseph A. DiMasi,Cherie Paquette +1 more
TL;DR: Data on the trends in the speed with which competitive entry has occurred in the pharmaceutical marketplace and the competitive nature of the industry's development of so-called ‘me-too’ drugs suggest that entry barriers have fallen over time for new drug.
Journal ArticleDOI
Switching prescription drugs to over the counter
TL;DR: The roles that pharmaceutical firms, healthcare organisations, and government regulatory agencies played in three recent switches that have fuelled global debate are illustrated: simvastatin in theUnited Kingdom, omeprazole in Sweden, and loratadine in the United States are illustrated.
Journal ArticleDOI
Comparing Patient Access to Pharmaceuticals in the UK and US
TL;DR: The US provides faster, more flexible access to most, but not all, of the UK-approved pharmaceuticals in the authors' sample, however, US patients have higher cost sharing than the UK and coverage is less evenly spread across the population.
Journal Article
Therapeutic recombinant proteins: trends in US approvals 1982 to 2002.
TL;DR: To determine trends in the clinical development and approval processes for therapeutic recombinant proteins, data for 270 products that entered clinical study in the period 1980 to 2002 were collected and analyzed.